Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA

Abstract

The phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway is critical for cellular growth and metabolism. Correspondingly, loss of function of PTEN, a negative regulator of PI3K, or activating mutations in AKT1, AKT2 or AKT3 have been found in distinct disorders featuring overgrowth or hypoglycemia. We performed exome sequencing of DNA from unaffected and affected cells from an individual with an unclassified syndrome of congenital progressive segmental overgrowth of fibrous and adipose tissue and bone and identified the cancer-associated mutation encoding p.His1047Leu in PIK3CA, the gene that encodes the p110α catalytic subunit of PI3K, only in affected cells. Sequencing of PIK3CA in ten additional individuals with overlapping syndromes identified either the p.His1047Leu alteration or a second cancer-associated alteration, p.His1047Arg, in nine cases. Affected dermal fibroblasts showed enhanced basal and epidermal growth factor (EGF)-stimulated phosphatidylinositol 3,4,5-trisphosphate (PIP3) generation and concomitant activation of downstream signaling relative to their unaffected counterparts. Our findings characterize a distinct overgrowth syndrome, biochemically demonstrate activation of PI3K signaling and thereby identify a rational therapeutic target.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Spectrum of overgrowth in individuals with activating PIK3CA mutations.
Figure 2: Segmental skeletal and fibroadipose overgrowth in individuals with activating PIK3CA mutations.
Figure 3: Identification of PIK3CA mutations in affected cells and tissues.
Figure 4: Hyperactivity of PI3K in cells harboring PIK3CA mutations.

Accession codes

Primary accessions

NCBI Reference Sequence

References

  1. 1

    Yuan, T.L. & Cantley, L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497–5510 (2008).

    CAS  Article  Google Scholar 

  2. 2

    Happle, R. The group of epidermal nevus syndromes Part I. Well defined phenotypes. J. Am. Acad. Dermatol. 63, 1–22, quiz 23–24 (2010).

    Article  Google Scholar 

  3. 3

    Lindhurst, M.J. et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N. Engl. J. Med. 365, 611–619 (2011).

    CAS  Article  Google Scholar 

  4. 4

    Carpten, J.D. et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439–444 (2007).

    CAS  Article  Google Scholar 

  5. 5

    Happle, R. Type 2 segmental Cowden disease vs. Proteus syndrome. Br. J. Dermatol. 156, 1089–1090 (2007).

    CAS  Article  Google Scholar 

  6. 6

    Biesecker, L. The challenges of Proteus syndrome: diagnosis and management. Eur. J. Hum. Genet. 14, 1151–1157 (2006).

    Article  Google Scholar 

  7. 7

    Oduber, C.E., van der Horst, C.M. & Hennekam, R.C. Klippel-Trenaunay syndrome: diagnostic criteria and hypothesis on etiology. Ann. Plast. Surg. 60, 217–223 (2008).

    CAS  Article  Google Scholar 

  8. 8

    Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).

    CAS  Article  Google Scholar 

  9. 9

    1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061–1073 (2010).

  10. 10

    Clark, J. et al. Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. Nat. Methods 8, 267–272 (2011).

    CAS  Article  Google Scholar 

  11. 11

    Mandelker, D. et al. A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane. Proc. Natl. Acad. Sci. USA 106, 16996–17001 (2009).

    CAS  Article  Google Scholar 

  12. 12

    Hon, W.C., Berndt, A. & Williams, R.L. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Oncogene published online, 10.1038/onc.2011.532 (28 November 2011).

  13. 13

    Biesecker, L.G. et al. Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. Am. J. Med. Genet. 84, 389–395 (1999).

    CAS  Article  Google Scholar 

  14. 14

    Carty, M.J., Taghinia, A. & Upton, J. Overgrowth conditions: a diagnostic and therapeutic conundrum. Hand Clin. 25, 229–245 (2009).

    Article  Google Scholar 

  15. 15

    Oduber, C.E. et al. A proposal for classification of entities combining vascular malformations and deregulated growth. Eur. J. Med. Genet. 54, 262–271 (2011).

    Article  Google Scholar 

  16. 16

    Chen, W.S. et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15, 2203–2208 (2001).

    CAS  Article  Google Scholar 

  17. 17

    Whiteman, E.L., Cho, H. & Birnbaum, M.J. Role of Akt/protein kinase B in metabolism. Trends Endocrinol. Metab. 13, 444–451 (2002).

    CAS  Article  Google Scholar 

  18. 18

    Hussain, K. et al. An activating mutation of AKT2 and human hypoglycemia. Science 334, 474 (2011).

    CAS  Article  Google Scholar 

  19. 19

    Poduri, A. et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 74, 41–48 (2012).

    CAS  Article  Google Scholar 

  20. 20

    Hawkins, P.T., Anderson, K.E., Davidson, K. & Stephens, L.R. Signalling through Class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34, 647–662 (2006).

    CAS  Article  Google Scholar 

  21. 21

    Yamamoto, S. et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J. Pathol. 225, 189–194 (2011).

    CAS  Article  Google Scholar 

  22. 22

    Miron, A. et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res. 70, 5674–5678 (2010).

    CAS  Article  Google Scholar 

  23. 23

    Engelman, J.A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351–1356 (2008).

    CAS  Article  Google Scholar 

  24. 24

    Adams, J.R. et al. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res. 71, 2706–2717 (2011).

    CAS  Article  Google Scholar 

  25. 25

    Meyer, D.S. et al. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res. 71, 4344–4351 (2011).

    CAS  Article  Google Scholar 

  26. 26

    Liu, P. et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms. Nat. Med. 17, 1116–1120 (2011).

    CAS  Article  Google Scholar 

  27. 27

    Kinross, K.M. et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J. Clin. Invest. 122, 553–557 (2012).

    CAS  Article  Google Scholar 

  28. 28

    Hafner, C. et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc. Natl. Acad. Sci. USA 104, 13450–13454 (2007).

    CAS  Article  Google Scholar 

  29. 29

    Tosi, L.L., Sapp, J.C., Allen, E.S., O'Keefe, R.J. & Biesecker, L.G. Assessment and management of the orthopedic and other complications of Proteus syndrome. J. Child. Orthop. 5, 319–327 (2011).

    Article  Google Scholar 

  30. 30

    Marsh, D.J. et al. Rapamycin treatment for a child with germline PTEN mutation. Nat. Clin. Pract. Oncol. 5, 357–361 (2008).

    CAS  Article  Google Scholar 

  31. 31

    Ellis, H., Logan, B.M. & Dixon, A.K. Human Sectional Anatomy: Atlas of Body Sections, CT and MRI Images 163 (Hodder-Arnold, London, 2007).

  32. 32

    Raffan, E. & Semple, R.K. Next generation sequencing—implications for clinical practice. Br. Med. Bull. 99, 53–71 (2011).

    CAS  Article  Google Scholar 

  33. 33

    Firmann, M. et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc. Disord. 8, 6 (2008).

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank L. Ivey, J.J. Johnston, V. Tasic, M. Walters and E. Choolun for support and advice. The authors are especially grateful to the subjects who participated in this research study and to the Proteus Syndrome Foundations of the United States and United Kingdom, who have supported and encouraged these individuals and our research efforts. V.E.R.P., S.O., D.B.S., I.B. and R.K.S. were supported by the Wellcome Trust (grants 097721/Z/11/Z, 80952/Z/06/Z, 078986/Z/06/Z, 098051/Z/05/Z and 091551/Z/10/Z), the UK Medical Research Council Centre for Obesity and Related Disorders and the UK National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. L.G.B., M.J.L., J.C.S. and A.M.W. were supported by the Intramural Research Program of the National Human Genome Research Institute. S.R., Q.Z. and M.J.O.W. were supported by the Biotechnology and Biological Sciences Research Council (BBSRC). We are grateful for access to exome sequence data from the CoLaus cohort, which was sequenced as part of a partnership between the Wellcome Trust Sanger Institute, the CoLaus principal investigators and the Quantitative Sciences department of GlaxoSmithKline. S.M.H. is supported by the Manchester NIHR Biomedical Research Centre.

Author information

Affiliations

Authors

Contributions

M.J.L., V.E.R.P., I.B., L.G.B. and R.K.S. designed the study and drafted the manuscript. M.J.L. and V.E.R.P. performed the research and analyzed the data. F.P., C.E.S., A.D. and I.B. performed analysis of whole-exome sequencing data and wrote the corresponding methods in the manuscript. J.C.S. provided clinical data and wrote the corresponding clinical descriptions. A.M.W. performed mutation assays and assisted with immunoblotting experiments. S.M.H., L.L.T., M.L.C., T.N.D., J.G., Z.G., V.R.S. and C.T. provided clinical data and/or fibroblast samples from affected individuals. S.R., Q.Z. and M.J.O.W. performed PIP3 quantification and data analysis. J.H. assisted with the collection of clinical data. M.P.G. assisted with immunoblotting experiments. T.H. performed histological analysis. A.K.D. interpreted imaging. S.O. and D.B.S. contributed to study design and reviewed the manuscript. L.G.B. and R.K.S. supervised the overall study.

Corresponding authors

Correspondence to Inês Barroso or Leslie G Biesecker or Robert K Semple.

Ethics declarations

Competing interests

I.B. and her spouse own stock in GlaxoSmithKline and the Incyte Corporation.

Supplementary information

Supplementary Text and Figures

Supplementary Tables 1–3, Supplementary Figures 1 and 2 and Supplementary Note (PDF 241 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lindhurst, M., Parker, V., Payne, F. et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet 44, 928–933 (2012). https://doi.org/10.1038/ng.2332

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing